Application of 19F magnetic resonance to study the efficacy of fluorine labeled drugs in the three-dimensional cultured breast cancer cells.

[1]  Risto Penttinen,et al.  Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy , 2009, Pharmacological Reviews.

[2]  Sami Kilpinen,et al.  Role of ErbB4 in Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[3]  A. Musolino,et al.  Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Purser,et al.  Fluorine in medicinal chemistry. , 2008, Chemical Society reviews.

[5]  David O'Hagan,et al.  Understanding organofluorine chemistry. An introduction to the C-F bond. , 2008, Chemical Society reviews.

[6]  Mangala Srinivas,et al.  Fluorine‐19 MRI for visualization and quantification of cell migration in a diabetes model , 2007, Magnetic resonance in medicine.

[7]  R. Mason,et al.  19F‐NMR detection of lacZ gene expression via the enzymic hydrolysis of 2‐fluoro‐4‐nitrophenyl β‐D‐galactopyranoside in vivo in PC3 prostate tumor xenografts in the mouse 1 , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  Xinrong Liu,et al.  Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Y. Barenholz,et al.  Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG‐independent, direct cytotoxic effects in cell cultures and in mice , 2006, The journal of gene medicine.

[10]  E. D. de Vries,et al.  Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Larson,et al.  Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Han van de Waterbeemd,et al.  Pharmacokinetics and Metabolism in Drug Design: SMITH: PHARMACOKINETICS AND METABOLISM IN DRUG DESIGN O-BK , 2006 .

[13]  J. Robertson,et al.  Endocrine treatment options for advanced breast cancer--the role of fulvestrant. , 2005, European journal of cancer.

[14]  Patrick J. Gaffney,et al.  Quantitative “magnetic resonance immunohistochemistry” with ligand‐targeted 19F nanoparticles , 2004 .

[15]  J. Bart,et al.  Preclinical characterisation of 111In‐DTPA‐trastuzumab , 2004, British journal of pharmacology.

[16]  Neal Rosen,et al.  Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors , 2004, Nature Biotechnology.

[17]  G. Loo,et al.  Disruption of mitochondria during tocotrienol-induced apoptosis in MDA-MB-231 human breast cancer cells. , 2004, Biochemical pharmacology.

[18]  A. Abbott Cell culture: Biology's new dimension , 2003, Nature.

[19]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[20]  I. Zuhorn,et al.  On the Mechanism of Cationic Amphiphile-mediated Transfection. To Fuse or not to Fuse: Is that the Question? , 2002, The Journal of Membrane Biology.

[21]  M. Brechbiel,et al.  A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. , 2002, Nuclear medicine and biology.

[22]  G. Hortobagyi,et al.  Targeting HER2: recent developments and future directions for breast cancer patients. , 2001, Seminars in oncology.

[23]  S. Kerwin,et al.  Synthesis, DNA cleavage, and cytotoxicity of a series of bis(propargylic) sulfone crown ethers. , 2001, Bioorganic & medicinal chemistry.

[24]  C. Moyes,et al.  3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. , 2001, Journal of medicinal chemistry.

[25]  D. Larsimont,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. , 2000, American journal of clinical pathology.

[26]  A. Sette,et al.  Identification of HER2/neu‐derived peptide epitopes recognized by gastric cancer‐specific cytotoxic T lymphocytes , 1998, International journal of cancer.

[27]  B. Dardzinski,et al.  Rapid tissue oxygen tension mapping using 19F inversion‐recovery echo‐planar imaging of P erfluoro‐15 ‐crown‐5‐ether , 1994, Magnetic resonance in medicine.

[28]  R. Kumar,et al.  Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. , 1994, The Journal of biological chemistry.

[29]  P. Arenaz,et al.  Genotoxic potential of crown ethers in mammalian cells: induction of sister-chromatid exchanges. , 1992, Mutation research.

[30]  J. Montgomery,et al.  Antibody-targeted liposomes: increase in specific toxicity of methotrexate-gamma-aspartate. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Martin,et al.  Extracellular matrix proteins give new life to cell culture , 1981, Hepatology.

[32]  H. Kleinman,et al.  Role of collagenous matrices in the adhesion and growth of cells , 1981, The Journal of cell biology.